Enolen's fast track designation by the FDA aims to expedite its development for localized prostate cancer treatment, addressing unmet medical needs. The localized delivery technology targets ...
Alessa Therapeutics ("Alessa"), a clinical-stage biopharmaceutical company advancing novel localized drug delivery technology for the treatment of early-stage prostate cancers, today announced that ...
Hosted on MSN
Key Information For Patients To Evaluate Prostate Cancer Treatment Options: Stage & Type Matter
Every prostate cancer journey begins with a clear understanding of the diagnosis. This isn’t a “one-size-fits-all” disease, and treatment plans are highly personalized. “When we’re evaluating a case ...
Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...
In preclinical prostate cancer models, HLD-0915 treatment resulted in tumor shrinkage and declines in prostate-specific antigen. The Food and Drug Administration (FDA) has granted Fast Track ...
Patients will be able to find out whether they have genes linked to cancer using a world-leading tool developed by the NHS.
Fast Track Designation Highlights Potential of Enolen to Address Unmet Medical Need for Patients with Low to Intermediate Risk, Localized Prostate Cancer Company Expects to Provide Initial Findings ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results